Other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS)

Page last updated: 25 January 2018

Instructions for PDF forms

The PDF forms on this page may not open correctly in your browser. Please use Microsoft Explorer or download the form to your computer before editing.

Life Saving Drugs Program (LSDP)

Through the LSDP, the Australian Government provides subsidised access, for eligible patients, to expensive life saving drugs for very rare life-threatening conditions.

The treating physician must submit a completed reapplication form to the LSDP by 1 May every year if they wish their patients to continue to receive subsidised treatment through the LSDP.

Review of the LSDP

On 9 April 2014, then Minister for Health, the Hon Peter Dutton MP, announced that the post-market review of the Life Saving Drugs Program (LSDP Review) would proceed.

The LSDP Review was an opportunity to review the current program in order to ensure that Australians with very rare conditions continue to have subsidised access to much-needed, expensive medicines.

The Review examined important issues such as access and equity, value for money and the future administration of the program.

Patients currently treated through the LSDP will continue to receive access to treatment, new patients may continue to apply for access to treatment and applications for new medicines seeking LSDP listing will continue to be considered as they arise.

Information regarding the Review of the LSDP is available from the PBS reviews web page.

LSDP Funding Criteria and Conditions

Subsidised access through the LSDP is granted in accordance with specified eligibility criteria and subject to certain conditions:
Life Saving Drugs Program Criteria and Conditions.

Before being considered for inclusion, a drug must first be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) and rejected on the basis of cost effectiveness. The Chief Medical Officer (CMO) advises the Minister for Health on drugs proposed to be included on the LSDP.

Medicines currently funded through the LSDP

There are currently thirteen medicines available to eligible patients for the treatment of nine conditions. To view the Guidelines and application forms, visit: For information regarding the management and dispensing of these expensive life saving drugs, please view the Drug Supply Fact Sheet (PDF 384 KB), Drug Supply Fact Sheet (Word 510 KB).

Imiglucerase (Cerezyme®), Velaglucerase (VPRIV®), Taliglucerase (Elelyso®) and Miglustat (Zavesca®) for the treatment of Gaucher disease (Type 1)


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Gaucher disease (Type 1) (PDF 2088 KB)
MS Excel spreadsheet for Gaucher disease (Type 1) (Excel 11 KB)

Cerezyme®, VPRIV®, Elelyso® and Zavesca® Product Information is available at the Therapeutic Goods Administration EBS website.

Agalsidase alfa (Replagal®) and Agalsidase beta (Fabrazyme®) for the treatment of Fabry Disease


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Fabry disease (PDF 1720 KB)
MS Excel spreadsheet for Fabry disease (Excel 11 KB)

Fabry disease Pain Diary (PDF 39 KB)
Fabry disease Pain Diary (Word 22 KB)

Fabrazyme® and Replagal® Product Information is available at the Therapeutic Goods Administration EBS website.

Laronidase (Aldurazyme®) for the treatment of Mucopolysaccharidosis Type I (MPS I)


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Mucopolysaccharidosis Type I (PDF 1267 KB)
MS Excel spreadsheet for Mucopolysaccharidosis Type I (Excel 76 KB)

Aldurazyme® Product Information is available at the Therapeutic Goods Administration EBS website.

Idursulfase (Elaprase®) for the treatment of Mucopolysaccharidosis Type II (MPS II)


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Mucopolysaccharidosis Type II (MPS II) (PDF 2709 KB)
MS Excel spreadsheet for Mucopolysaccharidosis Type II (MPS II) (Excel 76 KB)

Elaprase® Product Information is available at the Therapeutic Goods Administration EBS website.

Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPSIVA)


Life Saving Drugs Program (LSDP) guidelines and application form for subsidised treatment for Mucopolysaccharidosis Type IVA (MPSIVA) (PDF 3035 KB)
MS Excel spreadsheet for Mucopolysaccharidosis Type IVA (MPSIVA) (Excel 74 KB)
Vimizim® Product Information is available at the Therapeutic Goods Administration EBS website.

Galsulfase (Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI)


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Mucopolysaccharidosis Type VI (MPS VI) (PDF 1272 KB)
MS Excel spreadsheet for Mucopolysaccharidosis Type VI (MPS VI) (Excel 76 KB)

Naglazyme® Product Information is available at the Therapeutic Goods Administration EBS website.

Alglucosidase alfa (Myozyme®) for the treatment of Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe Disease


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe Disease (PDF 2221 KB)
MS Excel spreadsheet for Infantile-onset Pompe Disease (Excel 12 KB)
MS Excel spreadsheet for Juvenile Late-onset Pompe Disease (Excel 12 KB)
MS Excel spreadsheet for Adult Late-onset Pompe Disease (Excel 11 KB)

Myozyme® Product Information is available at the Therapeutic Goods Administration EBS website.

Eculizumab (Soliris®) for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)


Life Saving Drug Program (LSDP) guidelines and application form for subsidised treatment for Paroxysmal Nocturnal Haemoglobinuria (PNH) (PDF 1267 KB)
MS Excel spreadsheet for Paroxysmal Nocturnal Haemoglobinuria (PNH) (Excel 11 KB)

Meningococcal Vaccination Certificate (PDF 31 KB)
Meningococcal Vaccination Certificate (Word 504 KB)

Soliris® Product Information is available at the Therapeutic Goods Administration EBS website.

Nitisinone (Orfadin®) for the treatment of Hereditary Tyrosinaemia Type I


Life Saving Drugs Program (LSDP) guidelines and application for subsidised treatment for Hereditary Tyrosinaemia Type I (HTI) (PDF 2134 KB)
MS Excel spreadsheet for Hereditary Tyrosinaemia Type I (HTI) (Excel 9 KB)

Orfadin® Product Information is available at the Therapeutic Goods Administration EBS website.

Further Information

Life Saving Drugs Program
Phone: (02) 6289 2336
Fax: (02) 6289 8537
Email: LSDP team